Aura Biosciences, Inc. (AURA) Investor Relations Documents

Aura Biosciences, Inc. (AURA) investor relations documents from the company's IR site: 24 presentations; latest deck 2025-11-06. Read in-app with summaries. First-party data.

SIU 2025 Trial in Motion: Dr. Piyush Agarwal Presents Safety and Efficacy of AU-011, a Virus-Like Drug Conjugate, in Participants with NMIBC »: This Phase 1 trial of bel-sar (AU-011) in NMIBC demonstrates a favorable safety profile and clinical complete responses (cCR) via immune-mediated tumor killing.

Investor relations documents — source: company IR site

Published	Type	Document
2025-11-06	Presentation	SIU 2025 Trial in Motion: Dr. Piyush Agarwal Presents Safety and Efficacy of AU-011, a Virus-Like Drug Conjugate, in Participants with NMIBC »
2025-10-29	Presentation	SIU 2025: Dr. Seth Lerner Presents Immune Response and Preliminary Efficacy of bel-sar (AU-011), a first-in-class virus-like drug conjugate (VDC), in NMIBC »
2025-03-24	Presentation	EAU 2025: Dr. Lerner Presents Safety and efficacy of Bel-sar (AU-011), a Virus-like-Drug-Conjugate (VDC) in patients with Non-Muscle Invasive Bladder Cancer (NMIBC) »
2025-03-24	Presentation	EAU 2025: Research Forum – Virus-like Drug Conjugates (VDC), a paradigm shifting approach for the treatment of bladder cancer Mechanism, First Insights, and Future Directions »
2024-09-12	Presentation	Retina Society 2024: Dr. Kim Presents Final Results of a Phase 2 Trial of Suprachoroidal Administration of Bel-sar for Choroidal Melanoma »
2024-05-24	Presentation	ARVO 2024: Dr. Ma Presents Preclinical Belzupacap Sarotalocan Data for Cancers of the Ocular Surface »
2023-11-05	Presentation	AAO 2023: Dr. Shields Presents Phase 2 SC Belzupacap Sarotalocan Data »
2022-11-20	Presentation	SUO 2022: Dr. Shore Presents Trial in Progress Phase I NMIBC Data »
2022-10-02	Presentation	AAO 2022: Dr. Kim Presents Phase 2 SC Safety Belzupacap Sarotalocan Data »
2022-09-01	Presentation	EURETINA 2022: Dr. Jager Presents Preclinical Belzupacap Sarotalocan Data »
2022-09-01	Presentation	EURETINA 2022: Dr. Jager Presents Phase 1b/2 IVT and Phase 2 SC Belzupacap Sarotalocan Data »
2022-06-19	Presentation	ISOO 2022: Dr. Kim Presents Phase 2 SC AU-011 Data »
2022-06-19	Presentation	ISOO 2022: Educational Session Highlighting Retrospective Study of Belzupacap Sarotalocan versus Radiotherapy in Choroidal Melanoma »
2022-06-18	Presentation	ISOO 2022: Dr. Shields Presents Phase 1b/2 IVT AU-011 Data »
2022-05-02	Presentation	ARVO 2022: Aura Preclinical Data Presented »
2022-02-16	Presentation	Macula Society 2023: Dr. Kim Presents Phase 2 SC Safety Belzupacap Sarotalocan Data »
2021-11-20	Presentation	AAO 2021: Dr. Shields Presents Phase 1b/2 IVT AU-011 Data »
2021-11-20	Presentation	AAO 2021: Dr. Demirci Presents Phase 2 SC AU-011 Data »
2021-10-20	Presentation	ASRS 2021: Dr. Mruthyunjaya Presents Phase 2 AU-011 Data »
2021-09-20	Presentation	Euretina 2021: Aura Clinical Data Presented »
2021-05-04	Presentation	ARVO 2021: Aura Clinical Data Presented »
2021-04-14	Presentation	ARVO 2021: Aura Preclinical Data Presented »
2020-11-19	Presentation	AAO 2020: Dr. Carol Shields Presents Overview of AU-011 »
2020-06-10	Presentation	ARVO 2020: Aura Phase 1b/2 Results Presented »

AURA overview · AURA earnings · AURA financials · AURA KPIs · AURA ownership · AURA peers · AURA filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.